Swiss pharmaceutical company Novartis suspends part of its activities in Russia

Guardar

Geneva, 22 Mar The Swiss pharmaceutical giant reported today that it has suspended its capital investments and advertising and promotional activities in Russia, in compliance with international sanctions against that country for the invasion of Ukraine. The Basel firm also indicated in a statement that it will not initiate clinical trials in the country, nor will it incorporate new volunteers to those already under way. Despite these measures, Novartis stressed that the firm will maintain its commitments to Russia to ensure that there is access to its medicines in that market. The firm condemned in the statement the war in Ukraine, “an unprovoked act of violence that harms innocent people” and indicated that it has donated $3 million to organizations that aid the displaced, in addition to 600,000 packages of medicines including antibiotics, painkillers and treatments for cancer and cardiovascular diseases. Another major Swiss multinational, Nestlé, recently announced the suspension of all imports and exports of its products to and from Russia, with the exception of some essential foods, as well as its capital investment and advertising activities. CHIEF abc/ah